Copyright: ©Author(s) 2026.
World J Cardiol. Nov 26, 2026; 18(11): 124181
Published online Nov 26, 2026. doi: 10.4330/wjc.124181
Published online Nov 26, 2026. doi: 10.4330/wjc.124181
Figure 1 Efficacy of Xin-II in treating chronic heart failure.
A: Flowchart of the animal experiment; B: Graph showing body weight statistics for each group; C: Mortality statistics for each group; D: Cardiac function testing in animals (n = 3); E: Statistical results of echocardiography (n = 3). Data are presented as mean ± SEM. Statistical significance was determined by one-way analysis of variance followed by Tukey’s multiple comparisons test. aP < 0.05 (control vs model group); bP < 0.05 (model vs Xin-II group). NS: Not significant; CK: Creatine kinase; BNP: Brain natriuretic peptide; EF: Ejection fraction; FS: Fractional shortening; LVIDd: Left ventricular internal diastolic dimension; LVIDs: Left ventricular internal dimension in systole.
- Citation: Liu XJ, Cong Y, Zheng R, Li M, Xiu Z, Hu PF, Wu GH, Lianhua CG, Wan Q. Xin-II shows cardioprotective effects in a rat model of chronic heart failure: An integrated network pharmacology and transcriptomic. World J Cardiol 2026; 18(11): 124181
- URL: https://www.wjgnet.com/1949-8462/full/v18/i11/124181.htm
- DOI: https://dx.doi.org/10.4330/wjc.124181